Hillmen, Peter. 2009. “The Role of Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia (CLL) and the Achievement of Minimal Residual Disease Negativity in relapsed/Refractory CLL”. Hematology Meeting Reports (formerly Haematologica Reports) 1 (2). https://doi.org/10.4081/hmr.v1i2.226.